rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2012-8-2-201-204rpcardio-559Research ArticleNOTES FROM PRACTICEКЛИНИЧЕСКИЙ ОПЫТTELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDYТЕЛМИСАРТАН В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ КЛИНИЧЕСКИЙ РАЗБОРПодзолковВ. И.PodzolkovV. I.

профессор, д.м.н., заведующий кафедрой факультетской терапии №2 лечебного факультета

ТарзимановаА. И.TarzimanovaA. I.

к.м.н., доцент кафедры факультетской терапии №2 лечебного факультета

tarzimanova@mail.ruПервый Московский Государственный Медицинский Университет им. И.М. СеченоваРоссияI.M. Setchenov First Moscow State Medical UniversityRussian Federation20120301201682201204Copyright © Podzolkov V.I., Tarzimanova A.I., 20152015Подзолков В.И., Тарзиманова А.И.Podzolkov V.I., Tarzimanova A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/559

Data on angiotensin II receptor blockers, one of the main drug classes used in cardiology , are presented. The advantages of this drugs class are highlighted with the focus on telmisartan. Additionally clinical example of successful telmisartan application in patients with hypertension, high risk of cardiovascular complications, and obesity is presented.

Представлены данные о блокаторах рецепторов ангиотензина-II, которые являются одним из основных классов лекарственных препаратов, применяемых в кардиологии. Освещаются преимущества этой группы препаратов, при этом особое внимание уделено телмисартану. В дополнение представлен клинический пример успешного применения телмисартана у пациента с артериальной гипертензией, высоким риском осложнений и ожирением.

блокаторы рецепторов ангиотензина-IIтелмисартанартериальная гипертензияangiotensin II receptor blockerstelmisartanarterial hypertensionReferencesESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.National guidelines for diagnosis and treatment of hypertension (4th revision). Sistemye Gipertenzii 2010; (3) : 5-26. Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26.National guidelines for diagnosis and treatment of hypertension (4th revision). Sistemye Gipertenzii 2010; (3) : 5-26. Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26.Mancia G. Tolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo. Am J Hypertens 2002; 15 (Supp 1): A54Mancia G. Tolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo. Am J Hypertens 2002; 15 (Supp 1): A54Chazova I.E., Ratova L.G. The first generation sartans: Is there a future? Sistemnye Gipertenzii 2010; (4): 5–9. Russian (Чазова И.Е., Ратова Л.Г . Первое поколение сартанов: есть ли перспективы? Системные Гипертензии 2010; (4): 25-28).Chazova I.E., Ratova L.G. The first generation sartans: Is there a future? Sistemnye Gipertenzii 2010; (4): 5–9. Russian (Чазова И.Е., Ратова Л.Г . Первое поколение сартанов: есть ли перспективы? Системные Гипертензии 2010; (4): 25-28).Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000 Jul-Aug;28(4):149-67.Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000 Jul-Aug;28(4):149-67.The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008, 372: 1174–83.The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008, 372: 1174–83.Barnett AH, Bain SC, Bouter P et al. Diabetics exposed to telmisartan and enalapril study group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351 (19): 1952–61.Barnett AH, Bain SC, Bouter P et al. Diabetics exposed to telmisartan and enalapril study group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351 (19): 1952–61.Galle J, Schwedhelm E, Pinnetti S et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23 (10): 3174–83.Galle J, Schwedhelm E, Pinnetti S et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23 (10): 3174–83.Prasad B, Ravi N, Asma K et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009; 5: 129–40.Prasad B, Ravi N, Asma K et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009; 5: 129–40.Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy – rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker , telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677–86.Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy – rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker , telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677–86.Kurtz T ., Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009;32(10): 826–34.Kurtz T ., Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009;32(10): 826–34.

The authors declare that there are no conflicts of interest present.